Genes and the Nutrients They Change the Need For
2026-11-11Same post, two depths. Switch any time; the research version has the enzyme names, lab markers, and doses. Written from a research and education perspective: a model of what may be going on and what the published literature suggests would address it if the model is right, not medical advice or a treatment plan.
Most gene variants that matter for everyday health are not switches that cause a disease. They are dials that change how much of a nutrient your body needs, or which form it can use. This page is the table: for each of the genes that come up most, what the gene does, how the common variant changes it, what that means you need more of (or a different form of), what to test, and which gene report on this site covers it.
Two rules before the table. First, a variant tells you where to look, not what is wrong. Everything here needs the lab from the Lab Guide here to confirm the dial is actually turned down in you. Second, consumer DNA files read common variants well and rare ones badly, and every gene below is common-variant territory, so a 23andMe or Ancestry file is a reasonable place to start for these.
The methylation genes
MTR and MTRR. The enzyme that uses B12 and folate to recycle homocysteine, and the enzyme that repairs it when oxidative stress knocks the B12 out. Needs more of: B12 (hydroxocobalamin plus adenosylcobalamin), riboflavin (MTRR runs on it), antioxidant support. Test: homocysteine, MMA, holotranscobalamin. Report: Methylation.
CBS. The gate from the methylation cycle into the sulfur pathway that makes glutathione, taurine, and sulfate. Common variants nudge it faster or slower. Fast: homocysteine runs low and sulfur foods or supplements (NAC, MSM, garlic, eggs) may make you feel worse. Slow: homocysteine runs high and does not respond to folate and B12. Needs: B6 as P5P either way; molybdenum if sulfites bother you; go slowly with sulfur supplements if fast. Test: homocysteine, plasma amino acids, urinary sulfite. Report: Sulfur, Ammonia and Chemical Intolerance here.
SLC19A1 (the reduced folate carrier). The transporter that moves folate into most of your cells, and it works as a swap: folate in, thiamine's active form out. A common variant slows it modestly. Needs more of: folate in its reduced forms, and thiamine, because without enough active thiamine inside the cell there is nothing to swap. The pattern: high serum folate with low RBC folate. Test: serum and RBC folate together, whole-blood thiamine. Report: Methylation; Vitamin and Mineral Metabolism here.
PEMT. The enzyme that makes phosphatidylcholine from scratch when you do not eat enough choline, spending methyl groups to do it. Common variants slow it, and it is turned on by estrogen, so post-menopausal women and men with the variant are doubly short. Needs more of: choline from eggs and liver, or phosphatidylcholine. Test: no direct test; fatty liver, homocysteine, and a low egg intake are the clues. Report: Methylation; Lipids and Cardiovascular here.
MTHFD1, SHMT1, MTHFS. Other folate cycle enzymes; variants raise the choline and folate requirement (MTHFD1) or shift the glycine and serine balance. Needs more of: choline, folate, glycine. Report: Methylation.
The histamine and catecholamine genes
HNMT (C314T and others). The enzyme that clears histamine inside cells, spending a methyl group each time. Slow variants mean histamine from your own mast cells and from the brain's wake system lingers. Needs more of: methylation support (B2, B12, creatine, phosphatidylcholine); a low-histamine trial; apigenin and luteolin. Test: urinary N-methylhistamine, homocysteine. Report: Personalized Histamine Report here.
AOC1 (the DAO gene). The enzyme that breaks down histamine from food in the gut, which needs copper and B6. Slow variants mean wine, leftovers, and aged foods hit harder. Needs more of: copper (from liver, tested first), B6 as P5P, vitamin C; DAO supplements before meals; a low-histamine trial. Test: serum DAO activity, copper and ceruloplasmin, plasma P5P. Report: Personalized Histamine Report.
MAO-A and MAO-B. The enzymes that break down serotonin, norepinephrine, dopamine, and histamine using riboflavin's FAD. Slow MAO-A: more serotonin and norepinephrine, worse anxiety, worse reaction to tyramine foods (aged cheese, wine). Needs more of: riboflavin. Report: Neurotransmitters.
The vitamin genes
BCO1. The enzyme that cuts beta-carotene into vitamin A. Common variants cut conversion by half or more, so carrots and sweet potatoes do not count as vitamin A for you. Needs: preformed vitamin A from liver, cod liver oil, egg yolk, and dairy. Test: serum retinol with CRP. Report: Vitamin and Mineral Metabolism.
GC (the vitamin D binding protein) and VDR (the receptor). GC variants change how much of your measured vitamin D is actually free and usable, so two people with the same lab value can have different function; VDR variants change how strongly cells respond. Needs: a dose set by the lab and the response, not by a chart; magnesium and K2 alongside. Test: 25-OH-D with PTH and calcium; free vitamin D if available. Report: Vitamin and Mineral Metabolism.
CYP2R1 and CYP24A1. The enzyme that activates vitamin D in the liver and the enzyme that breaks it down. Slow activation means you need more; slow breakdown means a normal dose can push calcium too high. Test: 25-OH-D, calcium. Report: Vitamin and Mineral Metabolism.
TCN2 (transcobalamin) and FUT2. TCN2 carries B12 into cells; the common variant delivers it less well, so serum B12 can look fine while cells are short. FUT2 "non-secretors" absorb less B12 and have a different gut microbiome. Needs more of: B12, often in higher doses or by injection; the functional tests, not serum. Test: MMA, holotranscobalamin. Report: Vitamin and Mineral Metabolism; Gut Health here.
SLC19A2 and SLC19A3 (thiamine transporters). Variants lower thiamine uptake. Needs: benfotiamine or TTFD (forms that get in without the transporter). Test: whole-blood thiamine, transketolase activity. Report: Vitamin and Mineral Metabolism; Mitochondria here.
NBPF3, SLC23A1 (vitamin C transport), TTPA (vitamin E transport), SLC30A8 and SLC39A8 (zinc transporters). Each shifts a single nutrient's requirement; the Vitamin and Mineral report covers them.
The mineral genes
HFE (C282Y and H63D). The iron-sensing gene. Variants lower hepcidin and let iron in without a brake. One copy of C282Y or H63D raises iron modestly; two copies of C282Y (or C282Y with H63D) can cause hemochromatosis. Needs less of: iron, and never a supplement without ferritin and saturation; vitamin C in moderation with meals; donate blood if saturation runs high. Test: ferritin, transferrin saturation. Report: Vitamin and Mineral Metabolism.
TMPRSS6. Variants raise hepcidin and make iron hard to absorb; the person who stays iron deficient no matter what they eat. Needs: alternate-day iron with vitamin C, sometimes IV iron. Test: ferritin, saturation, hepcidin if available. Report: Vitamin and Mineral Metabolism.
SOD2 (A16V). The mitochondrial antioxidant enzyme, which needs manganese. The variant changes how well it gets into the mitochondria. Needs more of: manganese from food, and the whole antioxidant network (C, E, selenium, glutathione). Report: Mitochondria; Detoxification here.
DIO1 and DIO2. The enzymes that turn T4 into active T3. The DIO2 variant is the one behind "I feel better on T3," and both need selenium. Needs more of: selenium, iron, zinc. Test: free T3, reverse T3. Report: Thyroid.
ATP7B. The Wilson's disease gene. Carriers (one copy) may handle copper less well. Needs: caution with copper supplements; test before adding. Test: ceruloplasmin, copper. Report: Vitamin and Mineral Metabolism.
The fat, energy, and detox genes
FADS1 and FADS2. The enzymes that turn plant omega-3 (ALA) into EPA and DHA. The common minor alleles cut conversion sharply, so flax and chia do not become fish oil for you. Needs: EPA and DHA directly from fish or algae; GLA from borage or evening primrose if skin and inflammation suggest the omega-6 side is slow too. Test: omega-3 index and fatty acid panel. Report: Lipids and Cardiovascular.
APOE (e2, e3, e4). The cholesterol and brain lipid carrier. E4 carriers clear fat differently, absorb more dietary cholesterol, and have higher brain inflammation under load. Needs: more DHA (phospholipid form), less saturated fat combined with refined carbohydrate, more exercise, careful attention to sleep and alcohol. Test: ApoB, Lp(a), omega-3 index. Report: Lipids and Cardiovascular; Longevity here.
SLC22A5 (OCTN2, the carnitine transporter). Variants lower carnitine uptake into muscle and heart. Needs more of: carnitine (red meat; acetyl-L-carnitine). Test: plasma free carnitine, acylcarnitine profile. Report: Mitochondria.
CPT1A, ACADM, ACADVL, HADH. The fat-burning enzymes. Carriers of the common mild variants may crash with fasting and do badly on ketogenic diets; a true two-copy defect is a serious condition caught on newborn screening. Needs: regular carbohydrate-containing meals, no long fasts, carnitine, riboflavin (the acyl-CoA dehydrogenases run on FAD); MCT oil only if the block is not at MCAD. Test: acylcarnitine profile. Report: Mitochondria; Rare Metabolic here.
PPARG (Pro12Ala), TCF7L2, GCK. The blood sugar dials. TCF7L2 is the biggest common diabetes risk gene; PPARG Ala carriers are modestly protected. Needs: the substrate separation and walking rules from the metabolic post, magnesium, chromium second tier. Test: fasting insulin. Report: Blood Sugar and Insulin here.
GSTM1 and GSTT1 (deletions). Whole-gene deletions, carried by about half the population for GSTM1, of the enzymes that attach glutathione to toxins. Missing means more load on the other detox routes. Needs more of: cruciferous vegetables and sulforaphane (which switch on the backup enzymes), NAC and glycine for glutathione, lower exposure. Test: GGT, RBC glutathione. Report: Detoxification.
NAT2 (slow acetylator), CYP1A2 (slow caffeine), CYP2D6, CYP2C19, CYP2C9, SLCO1B1. Drug-handling genes that also handle food compounds. Slow NAT2 does worse with char-grilled meat; slow CYP1A2 should stop caffeine by noon. Report: Pharmacogenomics here; Detoxification.
SUOX and MOCS. Sulfite oxidase and its molybdenum cofactor. Slow means wine, dried fruit, and cured meat cause headaches and flushing. Needs more of: molybdenum. Test: urinary sulfite. Report: Sulfur, Ammonia and Chemical Intolerance.
NQO1, HMOX1, NFE2L2 (Nrf2). The antioxidant-response genes. Low-activity variants mean less built-in protection and more benefit from the foods that switch the system on. Needs more of: sulforaphane, riboflavin (NQO1 runs on FAD), the antioxidant network. Report: Detoxification; Longevity.
GAMT, AGAT, CKM. The creatine genes. Variants raise the benefit of eating creatine directly. Needs: creatine 5 g. Report: Athletic Performance here; Mitochondria.
The connective tissue and circadian genes
COL5A1, COL3A1, COL1A1, TNXB. The collagen and matrix genes. Common variants associate with laxity and injury risk; rare ones cause the named Ehlers-Danlos types. Needs more of: vitamin C, glycine, copper, zinc balanced with copper, and load (strength training) rather than stretch. Test: Beighton score and the connective tissue post here. Report: Connective Tissue here.
CLOCK, PER2, PER3, CRY1. The body clock genes behind morning and evening types. Not nutrient genes directly, but they set when you should eat and see light, and an evening type pushed onto a morning schedule runs short on sleep, which drains everything else. Needs: light and meal timing matched to your type; magnesium and glycine at night. Report: Sleep and Circadian here.
How to read your own file against this table
Pull the variants for these genes from your raw data, note which ones you carry and whether you have one or two copies, and then check the Lab Guide test for each. A variant with a normal functional lab is a dial you are already compensating for. A variant with an abnormal lab is a bottleneck, and the Nutrient Guide here has the form and the sequence. The gene reports on this site do this for a whole body system at once, with the interventions written out.
Educational content written from a research perspective, not medical advice. I am a PhD scientist, not a physician, and I do not diagnose, treat, cure, or prevent disease. Rare variants in several of these genes (HFE, ATP7B, CBS, the fatty acid oxidation and collagen genes) cause serious conditions that need a clinician and a confirmed clinical test, not a consumer file.
Framing
The variants below are common hypomorphs or transporter and regulatory polymorphisms, not Mendelian alleles. Each shifts the requirement for a nutrient, the form that can be used, or the tolerance of a dietary load, and each is silent until demand or a cofactor shortfall exposes it. Evidence grade is noted: A (mechanism established and intervention supported by human trials), B (mechanism established, intervention supported by observational or small interventional data), C (mechanism plausible, intervention extrapolated). Consumer arrays genotype most of these positions reliably; the rare pathogenic alleles in the same genes (HFE, ATP7B, CBS, CPT1A, ACADM, the collagens) require clinical confirmation. For each entry: function, variant effect, requirement shift, functional marker, and the gene report on this site.
One-carbon metabolism
| Gene (variant) | Function and effect | Requirement shift | Marker | Grade | Report |
|---|---|---|---|---|---|
| MTHFR (rs1801133 C677T, A222V; rs1801131 A1298C) | Reduces 5,10-methylene-THF to 5-MTHF; FAD-dependent. 677TT: thermolabile, reduced FAD affinity, about 30 to 35 percent residual activity; CT about 65 percent. 1298CC: modest reduction; compound heterozygosity additive | Riboflavin (FAD repletion rescues 677TT activity; RCTs show homocysteine and blood pressure reduction specifically in TT); folate as folinic acid or 5-MTHF rather than folic acid; magnesium | Homocysteine, RBC folate, EGRAC | A | Methylation here |
| MTR (rs1805087 A2756G) | Methionine synthase; cobalamin-dependent remethylation | Cobalamin (hydroxocobalamin plus adenosylcobalamin); folate | Homocysteine, MMA, holoTC | B | Methylation |
| MTRR (rs1801394 A66G) | Methionine synthase reductase; FAD-dependent reactivation of oxidized cob(II)alamin; 66GG lowers affinity for methionine synthase | Riboflavin, cobalamin, antioxidant capacity (oxidative stress inactivates the MTR cofactor) | Homocysteine, MMA | B | Methylation |
| CBS (rs234706 C699T, rs5742905 I278T carriers, 844ins68) | Cystathionine beta-synthase; PLP- and heme-dependent, SAMe-activated; gates transsulfuration. 699T associates with higher activity (lower homocysteine); I278T and other hypomorphs lower it | Up-regulated: cautious introduction of sulfur agents (NAC, MSM, ALA), molybdenum if sulfite-sensitive, taurine and glycine. Down-regulated: P5P, with folate and B12 failing to normalize homocysteine | Homocysteine, plasma amino acids (cystathionine, taurine), urinary sulfite | B | Sulfur, Ammonia and Chemical Intolerance here |
| SLC19A1, reduced folate carrier (rs1051266 80G>A) | Anion exchanger importing reduced folates against intracellular organic phosphate efflux; thiamine pyrophosphate is a transported substrate. 80AA modestly lowers transport | Reduced folates; thiamine, since low intracellular TPP weakens the exchange gradient (the high-serum, low-RBC folate pattern) | Serum and RBC folate together, whole-blood TDP | C for the thiamine coupling; B for the variant | Methylation; Vitamin and Mineral Metabolism here |
| PEMT (rs7946 V175M; rs12325817) | Phosphatidylethanolamine N-methyltransferase; de novo phosphatidylcholine spending three SAMe; estrogen-inducible. Variants reduce activity and raise susceptibility to choline-deficiency organ dysfunction, most strongly in post-menopausal women and men | Dietary choline 550 mg or more (eggs, liver), or phosphatidylcholine | No direct marker; hepatic steatosis, CK, homocysteine | A (choline depletion studies) | Methylation; Lipids and Cardiovascular here |
| MTHFD1 (rs2236225 G1958A) | Trifunctional folate enzyme; 1958AA raises choline requirement and NTD risk | Choline, folate | Homocysteine | B | Methylation |
| SHMT1 (rs1979277), MTHFS, DHFR 19-bp deletion | One-carbon unit supply, folinic acid activation, folic acid reduction | Glycine and serine balance; folinic acid tolerated; avoid folic acid (DHFR deletion raises unmetabolized folic acid) | RBC folate, plasma glycine and serine | C | Methylation |
| BHMT (rs3733890 R239Q) | Betaine-homocysteine methyltransferase, the folate-independent remethylation route | Betaine or choline when the folate arm is limited | Homocysteine, plasma betaine | B | Methylation |
Monoamine and histamine clearance
| Gene (variant) | Function and effect | Requirement shift | Marker | Grade | Report |
|---|---|---|---|---|---|
| COMT (rs4680 V158M) | Catechol-O-methyltransferase; SAMe- and magnesium-dependent clearance of catecholamines and catechol estrogens. Met/Met: three- to four-fold lower activity, slower catecholamine clearance, higher 4-OH estrogen persistence | Magnesium; methyl-sparing support (creatine, phosphatidylcholine) before methyl donors; caution with SAMe, methylfolate, and high caffeine; cruciferous and fiber support for estrogen clearance | RBC magnesium, homocysteine, urinary estrogen metabolites | B | Neurotransmitters here; Methylation |
| HNMT (rs11558538 C314T, T105I; rs1050891) | Histamine N-methyltransferase; SAMe-dependent intracellular histamine clearance. 314T lowers activity about 30 to 50 percent | Methylation support (riboflavin, cobalamin, methyl-sparing substrates); histamine load reduction; apigenin, luteolin | Urinary N-methylhistamine, homocysteine | B | Personalized Histamine Report here |
| AOC1, diamine oxidase (rs10156191, rs1049742, rs1049793, rs2052129) | Copper- and TPQ-dependent extracellular histamine oxidation at the gut mucosa. Minor alleles reduce activity and associate with histamine intolerance | Copper (dietary, confirmed by ceruloplasmin), P5P, ascorbate; DAO with meals; histamine restriction trial | Serum DAO activity, copper and ceruloplasmin, plasma PLP | B | Personalized Histamine Report |
| MAOA (uVNTR, rs6323), MAOB (rs1799836) | FAD-dependent oxidative deamination of serotonin, norepinephrine, dopamine (MAOA) and dopamine and histamine metabolites (MAOB). Low-activity MAOA: tyramine sensitivity, higher serotonergic and noradrenergic tone | Riboflavin; tyramine awareness; caution with serotonergic and noradrenergic agents | Urinary 5-HIAA, VMA, HVA (organic acids) | B | Neurotransmitters |
| GCH1 (rs8007267, rs3783641), QDPR, DHFR | BH4 synthesis and recycling; BH4 is the cofactor for TH, TPH, PAH, and NOS. Low-activity haplotypes associate with pain sensitivity and reduced monoamine synthesis | Folate (DHFR-mediated BH2 to BH4 salvage), ascorbate, antioxidant capacity; the rapid monoamine response to 5-MTHF is plausibly BH4-mediated | Plasma biopterin ratios (research), neopterin | C | Neurotransmitters |
Vitamin transport and activation
| Gene (variant) | Function and effect | Requirement shift | Marker | Grade | Report |
|---|---|---|---|---|---|
| BCO1 (rs12934922 R267S, rs7501331 A379V) | Beta-carotene 15,15'-monooxygenase. Minor alleles reduce conversion 32 to 69 percent; conversion falls further with rising retinol status | Preformed retinol (liver, cod liver oil, egg yolk, dairy); carotenoids are not a reliable vitamin A source | Serum retinol and RBP with CRP; plasma beta-carotene elevated relative to retinol | A | Vitamin and Mineral Metabolism |
| GC, vitamin D binding protein (rs7041, rs4588; Gc1f, Gc1s, Gc2) | Binds 85 to 90 percent of circulating 25-OH-D; isoforms differ in affinity and concentration. Gc2 carriers have lower total 25-OH-D at similar free vitamin D | Dose to response and to PTH and calcium rather than to a fixed total 25-OH-D; free 25-OH-D where available | 25-OH-D, PTH, calcium, free 25-OH-D | B | Vitamin and Mineral Metabolism |
| VDR (FokI rs2228570, BsmI rs1544410, TaqI rs731236) | Receptor sensitivity and expression | Higher vitamin D intake to reach the same transcriptional effect in low-responder genotypes; magnesium, K2 | 25-OH-D, PTH | B | Vitamin and Mineral Metabolism |
| CYP2R1 (rs10741657), CYP24A1 (rs6013897; rare loss-of-function) | Hepatic 25-hydroxylation; catabolism. CYP2R1 minor alleles lower 25-OH-D per unit intake; CYP24A1 loss-of-function produces hypercalcemia on ordinary doses | CYP2R1: higher D3 dose; CYP24A1: dose cautiously with calcium monitoring | 25-OH-D, calcium | B | Vitamin and Mineral Metabolism |
| TCN2 (rs1801198 776C>G, R259P) | Transcobalamin II; GG lowers holoTC and cellular cobalamin delivery at the same total B12 | Higher cobalamin dose, parenteral where MMA stays elevated; functional markers rather than serum B12 | HoloTC, MMA | B | Vitamin and Mineral Metabolism |
| FUT2 (rs601338 W143X, non-secretor) | Secretor status; non-secretors have lower serum B12 (altered gastric and microbial handling) and a distinct microbiome; protection against norovirus | Cobalamin; attention to gut health | MMA, holoTC | B | Vitamin and Mineral Metabolism; Gut Health here |
| SLC19A2 (THTR1), SLC19A3 (THTR2), SLC25A19 | Thiamine uptake and mitochondrial TPP import. Hypomorphs raise the thiamine requirement; biallelic SLC19A3 loss is biotin-thiamine-responsive basal ganglia disease | Benfotiamine or TTFD (transporter-independent uptake); magnesium | Whole-blood TDP, transketolase activity | B | Vitamin and Mineral Metabolism; Mitochondria here |
| SLC23A1 and SLC23A2 (SVCT1 and SVCT2) | Ascorbate transport; variants lower plasma and tissue ascorbate | Divided-dose ascorbate; liposomal where transport is limiting | Plasma ascorbate | C | Vitamin and Mineral Metabolism |
| TTPA (rs6994076) | Alpha-tocopherol transfer protein; variants modestly lower circulating alpha-tocopherol | Mixed tocopherols and tocotrienols with fat | Lipid-adjusted alpha-tocopherol | C | Vitamin and Mineral Metabolism |
| SLC30A8 (rs13266634 R325W), SLC39A8 (rs13107325 A391T) | Zinc transporters (beta-cell ZnT8; manganese and zinc ZIP8). SLC39A8 391T lowers manganese and affects glycosylation and blood pressure | Zinc balanced with copper; manganese from food for SLC39A8 | Plasma zinc, whole-blood manganese | B | Vitamin and Mineral Metabolism |
| NBPF3 (rs4654748) | Associates with lower plasma PLP | P5P | Plasma PLP | C | Vitamin and Mineral Metabolism |
Iron, copper, selenium, thyroid
| Gene (variant) | Function and effect | Requirement shift | Marker | Grade | Report |
|---|---|---|---|---|---|
| HFE (rs1800562 C282Y, rs1799945 H63D) | Hepcidin regulation. C282Y homozygotes and C282Y/H63D compound heterozygotes are at risk of hemochromatosis (penetrance incomplete, higher in men); single copies raise iron indices modestly | Iron restriction; no iron supplementation without ferritin and saturation; moderate ascorbate with meals; phlebotomy per hepatology when indicated; vitamin C and alcohol caution | Ferritin, transferrin saturation (over 45 percent triggers genotyping) | A | Vitamin and Mineral Metabolism |
| TMPRSS6 (rs855791 V736A) | Matriptase-2 suppresses hepcidin; the 736A allele raises hepcidin and lowers iron absorption, associated with iron-refractory iron deficiency | Alternate-day iron with ascorbate, parenteral iron where oral fails | Ferritin, saturation, hepcidin | B | Vitamin and Mineral Metabolism |
| ATP7B (carriers of pathogenic alleles; rs1801243) | Hepatic copper export and ceruloplasmin loading. Heterozygotes may show mildly altered copper indices | Caution with copper supplementation; test before adding | Ceruloplasmin, serum and free copper | B | Vitamin and Mineral Metabolism |
| SOD2 (rs4880 A16V) | Manganese superoxide dismutase; the Val allele alters mitochondrial import efficiency | Manganese from food; the antioxidant network (ascorbate, tocopherols, selenium, glutathione) | 8-OHdG, F2-isoprostanes, RBC glutathione | B | Mitochondria; Detoxification here |
| GPX1 (rs1050450 P198L), SELENOP (rs3877899), SELENOS | Selenoprotein activity and transport; variants raise the selenium intake needed for the same enzyme activity | Selenium 100 to 200 mcg (selenomethionine or two Brazil nuts) | Plasma selenium, GPX activity, free T3 | B | Thyroid here |
| DIO1 (rs2235544), DIO2 (rs225014 T92A) | Type 1 and 2 deiodinases, selenium-dependent T4 to T3 conversion. DIO2 92A associates with lower tissue T3 and with symptomatic benefit from combination T4 plus T3 therapy in some trials | Selenium, iron, zinc; discussion of T3-containing therapy with the prescriber in symptomatic DIO2 carriers | Free T3, reverse T3, free T3 to reverse T3 ratio | B | Thyroid |
| TPO, TG, TSHR, PDE8B | Thyroid synthesis and signaling variants altering TSH set point | Iodine adequacy without excess; selenium | TSH, free T4, free T3, TPO antibodies | C | Thyroid |
Lipids, energy, and detoxification
| Gene (variant) | Function and effect | Requirement shift | Marker | Grade | Report |
|---|---|---|---|---|---|
| FADS1 (rs174547, rs174546), FADS2 (rs174575) | Delta-5 and delta-6 desaturases. Minor-allele haplotypes reduce conversion of ALA to EPA and DHA and of LA to AA, among the strongest common determinants of plasma fatty acid composition | Preformed EPA and DHA (marine or algal); GLA where the delta-6 step is limiting; ALA is not a substitute | Omega-3 index, fatty acid panel (DGLA to AA, EPA to ALA ratios) | A | Lipids and Cardiovascular |
| APOE (rs429358, rs7412; e2, e3, e4) | Lipoprotein clearance, brain lipid transport, neuroinflammation. E4: higher LDL and cholesterol absorption, impaired DHA delivery to brain, higher inflammatory response; e2/e2: type III hyperlipoproteinemia risk | E4: DHA (phospholipid form preferentially), limit saturated fat combined with high glycemic load, exercise, sleep, alcohol restriction; e2: triglyceride and remnant attention | ApoB, Lp(a), omega-3 index, triglycerides | B | Lipids and Cardiovascular; Longevity here |
| SLC22A5 (OCTN2; rs274567 and others) | Sodium-dependent carnitine transporter in muscle, heart, kidney. Hypomorphs lower tissue carnitine; biallelic loss is primary carnitine deficiency | Carnitine (dietary red meat; acetyl-L-carnitine or L-carnitine) | Plasma free carnitine, acylcarnitine profile | B | Mitochondria |
| CPT1A (rs80356779 P479L in Arctic populations; common mild variants), ACADM (rs77931234 K329E carriers), ACADVL, HADH, ETFDH | Fatty acid oxidation enzymes. Carriers of common hypomorphs may show fasting intolerance and exercise-induced symptoms; biallelic pathogenic alleles are newborn-screened disorders | Regular carbohydrate-containing meals, avoidance of prolonged fasting and ketogenic strategies, carnitine, riboflavin (FAD for the acyl-CoA dehydrogenases and ETF/ETFDH); MCT oil only if the block is not at ACADM | Acylcarnitine profile, organic acids | B | Mitochondria; Rare Metabolic here |
| PPARG (rs1801282 Pro12Ala), TCF7L2 (rs7903146), GCK, KCNJ11, SLC2A2 | Insulin sensitivity and secretion variants. TCF7L2 T is the largest common type 2 diabetes risk allele; PPARG Ala is protective | Substrate separation, postprandial walking, magnesium, resistance training; chromium and inositol as second tier | Fasting insulin, HOMA-IR, CGM | B | Blood Sugar and Insulin here |
| GSTM1 and GSTT1 (homozygous deletion) | Glutathione S-transferases; null genotype means no enzyme (about 50 percent and 20 percent of Europeans respectively). Load shifts to GSTP1 and other phase II routes | Cruciferous vegetables and sulforaphane (Nrf2 induction of the remaining GSTs, NQO1, GCL), NAC and glycine, exposure reduction | GGT, RBC glutathione | B | Detoxification |
| GSTP1 (rs1695 I105V) | The remaining GST under load; 105V alters substrate specificity | As above | GGT | C | Detoxification |
| NQO1 (rs1800566 P187S) | Two-electron quinone reduction; 187SS has near-absent activity (protein instability) | Riboflavin (FAD cofactor), Nrf2 inducers, antioxidant network; caution with quinone-forming exposures (benzene, some drugs) | B | Detoxification | |
| NAT2 (slow acetylator haplotypes) | Arylamine N-acetyltransferase; slow acetylators handle heterocyclic amines, isoniazid, sulfonamides, and hydralazine more slowly | Limit char-grilled and smoked meat; drug dose awareness | A (pharmacogenomic) | Pharmacogenomics here; Detoxification | |
| CYP1A2 (rs762551, *1F slow), CYP2D6, CYP2C19, CYP2C9, SLCO1B1, VKORC1 | Phase I and transport pharmacogenes with dietary relevance (caffeine, cruciferous and char-grilled compounds, statin myopathy, warfarin) | CYP1A2 slow: caffeine cutoff by noon; SLCO1B1: statin choice and CoQ10; VKORC1: vitamin K consistency on warfarin | A (CPIC) | Pharmacogenomics | |
| SUOX, MOCS1/2/3, GPHN | Sulfite oxidase and molybdenum cofactor synthesis. Mild hypomorphs produce sulfite sensitivity; biallelic loss is severe neonatal disease | Molybdenum 150 to 300 mcg; limit sulfite-preserved foods; slow sulfur introduction | Urinary sulfite, plasma amino acids (S-sulfocysteine in severe cases) | C (mild variants) | Sulfur, Ammonia and Chemical Intolerance |
| HMOX1 ((GT)n promoter repeat; not read by arrays), NFE2L2 (promoter variants), KEAP1 | Heme oxygenase-1 and the Nrf2 axis; long HMOX1 repeats lower inducibility | Nrf2 inducers (sulforaphane, curcumin, EGCG), antioxidant network | C | Detoxification; Longevity | |
| GAMT, GATM (AGAT), CKM (rs8111989) | Creatine synthesis (about 40 percent of daily SAMe) and muscle creatine kinase; variants increase the benefit of dietary creatine | Creatine monohydrate 5 g | Plasma guanidinoacetate (inborn errors) | B | Athletic Performance here; Mitochondria |
Connective tissue and circadian
| Gene (variant) | Function and effect | Requirement shift | Marker | Grade | Report |
|---|---|---|---|---|---|
| COL5A1 (rs12722), COL1A1 (rs1800012 Sp1), COL3A1, TNXB, LOX, PLOD1 | Fibrillar collagen, tenascin-X, cross-linking and hydroxylation. Common variants associate with laxity and tendon injury; rare pathogenic alleles define the EDS types | Ascorbate, glycine (collagen peptides), copper (lysyl oxidase), zinc balanced with copper, iron; mechanical load rather than stretch; avoid fluoroquinolones | Beighton score, clinical phenotype; echocardiogram where vascular types are possible | B | Connective Tissue here |
| CLOCK (rs1801260), PER2, PER3 (VNTR), CRY1 (splice variant) | Core clock genes setting chronotype and period length; an evening chronotype on an early schedule produces chronic sleep restriction | Light and meal timing matched to chronotype; magnesium and glycine at night; melatonin at chronobiotic doses for phase shifting | Salivary cortisol curve, dim-light melatonin onset (research) | B | Sleep and Circadian here |
| HLA-DQ2 and DQ8 | Celiac susceptibility (necessary, not sufficient); absence excludes celiac disease with high negative predictive value | Celiac serology while consuming gluten in carriers with symptoms | tTG IgA with total IgA | A | Gut Health |
Working method
Genotype assigns a prior; the functional marker tests it; the presentation is what the model must explain. A variant with a normal functional marker is a compensated dial and needs no action beyond awareness of the load that would expose it. A variant with an abnormal marker is a bottleneck, and the Nutrient Guide here gives the form and the sequencing. Variants in the same pathway are additive (MTHFR with MTRR with SLC19A1; COMT with HNMT with AOC1; FADS with APOE), which is why the gene reports on this site are organized by body system rather than by single gene.
Educational and research content, not medical advice. The author holds a PhD in cellular and molecular nutrition, is not a licensed physician, and does not diagnose, treat, cure, or prevent disease. Rare pathogenic alleles in HFE, ATP7B, CBS, the fatty acid oxidation genes, SUOX and MOCS, and the collagen genes require clinical genetic confirmation and specialist management; consumer array calls for rare variants are unconfirmed.
